dc.contributor.author | Patel, B | en_US |
dc.contributor.author | Rai, L | en_US |
dc.contributor.author | Buck, G | en_US |
dc.contributor.author | Richards, SM | en_US |
dc.contributor.author | Mortuza, Y | en_US |
dc.contributor.author | Mitchell, W | en_US |
dc.contributor.author | Gerrard, G | en_US |
dc.contributor.author | Moorman, AV | en_US |
dc.contributor.author | Duke, V | en_US |
dc.contributor.author | Hoffbrand, AV | en_US |
dc.contributor.author | Fielding, AK | en_US |
dc.contributor.author | Goldstone, AH | en_US |
dc.contributor.author | Foroni, L | en_US |
dc.date.accessioned | 2024-01-09T11:53:57Z | |
dc.date.issued | 2010-01 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/93642 | |
dc.description.abstract | The predictive value of molecular minimal residual disease (MRD) monitoring using polymerase chain reaction amplification of clone-specific immunoglobulin or T-cell Receptor rearrangements was analysed in 161 patients with non T-lineage Philadelphia-negative acute lymphoblastic leukaemia (ALL) participating in the UK arm of the international ALL trial UKALL XII/Eastern Cooperative Oncology Group (ECOG) 2993. MRD positivity (> or =10(-4)) in patients treated with chemotherapy alone was associated with significantly shorter relapse-free survival (RFS) at several time-points during the first year of therapy. MRD status best discriminated outcome after phase 2 induction, when the relative risk of relapse was 8.95 (2.85-28.09)-fold higher in MRD-positive (> or =10(-4)) patients and the 5-year RFS 15% [95% confidence interval (CI) 0-40%] compared to 71% (56-85%) in MRD-negative (<10(-4)) patients (P = 0.0002) When MRD was detected prior to autologous stem cell transplantation (SCT), a significantly higher rate of treatment failure was observed [5-year RFS 25% (CI 0-55%) vs. 77% (95% CI 54-100%) in MRD-negative/<10(-4), P = 0.01] whereas in recipients of allogeneic-SCT in first complete remission, MRD positivity pre-transplant did not adversely affect outcome. These data provide a rationale for introducing MRD-based risk stratification in future studies for the delineation of those at significant risk of treatment failure in whom intensification of therapy should be evaluated. | en_US |
dc.format.extent | 80 - 89 | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Br J Haematol | en_US |
dc.subject | Adolescent | en_US |
dc.subject | Adult | en_US |
dc.subject | Child | en_US |
dc.subject | Epidemiologic Methods | en_US |
dc.subject | Hematopoietic Stem Cell Transplantation | en_US |
dc.subject | Humans | en_US |
dc.subject | Immunophenotyping | en_US |
dc.subject | Middle Aged | en_US |
dc.subject | Neoplasm, Residual | en_US |
dc.subject | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | en_US |
dc.subject | Prognosis | en_US |
dc.subject | Recurrence | en_US |
dc.subject | Treatment Failure | en_US |
dc.subject | Treatment Outcome | en_US |
dc.subject | Young Adult | en_US |
dc.title | Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. | en_US |
dc.type | Article | |
dc.identifier.doi | 10.1111/j.1365-2141.2009.07941.x | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/19863538 | en_US |
pubs.issue | 1 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 148 | en_US |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |